Skip to main content

Table 1 Segmented regression analysis on monthly adjusted number of prescription of the six antihypertensive drug classes

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Variables

β1(a)

β2(b)

β3(c)

β4(d)

β5(e)

β6(f)

β7(g)

ACEIs prescription proportion (%)

−0.02 (−0.2, −0.01)

−0.30 (−0.44, −0.16)

0.013 (0.007, 0.02)

---

---

---

---

Adjusted number of prescriptions

  ACEIs

135.7 (117.8, 153.6)

---

−149.9 (−181.4, −118.4)

---

---

---

---

  ARBs

65.9 (58.7, 72.0)

---

−67.2 (−79.8, −54.6)

---

---

---

---

  Diuretics

−55.4 (−61.9, −48.9)

---

---

---

---

---

---

  CCBs

90.4 (77.0, 103.9)

---

−77.4 (−101.1, −53.8)

---

---

---

---

  BBs

−102.7 (−119.0, −86.5)

---

−75.3 (−98.3, −52.4)

---

---

---

---

  “Others”

−3.0 (−4.9, −1.0)

---

−15.6 (−21.1, −10.1)

---

---

---

---

  1. Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy; (c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change following generic perindopril availability; (g)trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blocker